OITBpathway V. o. G, Eupen, Belgium.
Department of Health Convergence, Ewha Womans University, Seoul, South Korea.
Expert Rev Pharmacoecon Outcomes Res. 2024 Nov;24(9):1061-1066. doi: 10.1080/14737167.2024.2398482. Epub 2024 Sep 2.
This paper summarizes the results from a forum of healthcare experts, academia representatives, and public agency officials from emerging and established market countries on Value-Based Healthcare (VBHC) and Health Technology Assessment (HTA). Presentations from experts provided insights into current developments and challenges, followed by interactive roundtable discussions. Emerging markets have unique healthcare systems, patient populations, resource constraints and needs.
Each roundtable explored specific topics including the role of HTA and Real-world evidence (RWE) in healthcare decision-making, challenges in biosimilar value assessment and incorporating non-price criteria reflecting context-related specifications of emerging markets such as the multifaceted nature of value in healthcare decision-making, emphasizing stakeholder perspectives and system complexities.
RWE emerged as important in understanding biosimilar value recognition and decision-making processes, with insights into its applications and challenges. Recommendations were provided for utilizing Multi-Criteria Decision Analysis (MCDA) in pharmaceutical procurement, particularly for off-patent medicines, underscoring the importance of comprehensive evaluation frameworks and adherence to value-based principles. Overall findings suggest avenues for collaboration between industry, academia, and public agencies to address implementation barriers and promote equitable, efficient, and high-quality healthcare systems in emerging markets through public-private partnerships, joint capacity building and training initiatives, and knowledge transfers.
本文总结了医疗保健专家、学术界代表和新兴及成熟市场国家公共机构官员关于基于价值的医疗保健（VBHC）和健康技术评估（HTA）的论坛成果。专家的演讲深入探讨了当前的发展和挑战，随后进行了互动式圆桌讨论。新兴市场具有独特的医疗保健系统、患者群体、资源限制和需求。
每个圆桌会议都探讨了特定主题，包括 HTA 和真实世界证据（RWE）在医疗保健决策中的作用、生物类似药价值评估中的挑战以及纳入反映新兴市场背景相关规范的非价格标准，如医疗保健决策中价值的多面性，强调利益相关者的观点和系统的复杂性。
RWE 在理解生物类似药价值识别和决策过程中显得尤为重要，为其应用和挑战提供了深入了解。为药品采购（特别是非专利药品）中使用多标准决策分析（MCDA）提供了建议，强调了全面评估框架和遵循基于价值的原则的重要性。总体研究结果表明，通过公私合作伙伴关系、联合能力建设和培训举措以及知识转让，可以为行业、学术界和公共机构之间的合作提供途径，以解决新兴市场中实施障碍，并通过公共-私人伙伴关系、联合能力建设和培训举措以及知识转让，促进公平、高效和高质量的医疗保健系统。
